Novo Nordisk A/S (NVO) Stock Forecast & Price Target

NVO Forecast - Frequently Asked Questions

What is Novo Nordisk A/S's forecast for 2025?

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $81.00, with a high forecast of $160.00 and a low forecast of $54.00.

Should I buy or sell Novo Nordisk A/S stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There is currently 1 sell rating, 11 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.

Does Novo Nordisk A/S's stock price have much upside?

According to analysts, Novo Nordisk A/S's stock has a predicted upside of 47.43% based on their 12-month stock forecasts.

Has Novo Nordisk A/S been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Novo Nordisk A/S's stock had 4 upgrades and 4 downgrades by analysts.

What analysts cover Novo Nordisk A/S?

Novo Nordisk A/S has been rated by research analysts at Barclays, BNP Paribas, BNP Paribas Exane, Dbs Bank, Hsbc Global Res, HSBC, Sanford C. Bernstein, TD Cowen, UBS Group, and Zacks Research in the past 90 days.

Do Wall Street analysts like Novo Nordisk A/S more than its competitors?

Analysts like Novo Nordisk A/S less than other "medical" companies. The consensus rating for Novo Nordisk A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVO compares to other companies.